Annual Report

Overview

The report describes completion of the ABNCoV2 Phase III trial and validation of the ExpreS2 platform. It also highlights manufacturing and preclinical progress for the ES2B-C001 breast cancer vaccine. Collaborative projects advanced across influenza and malaria, while the company secured major grant support for the Nipah vaccine consortium. Group net sales were SEK 7,050 thousand in 2023.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2023
Period: 1 January 2023 – 31 December 2023
Language: English
Pages
File size

Reporting standards, commitments and assurance details are available with a free account.

Standards

Other

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services